Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma
Adoptive cell immunotherapy has been a hot spot in tumor research in recent years. Chimeric antigen receptor T cells (CAR-T) have achieved great success in hematological tumors and have changed the current tumor treatment landscape to a certain extent. However, the application of CAR-T therapy in cl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-12-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0664 |
| _version_ | 1797372841879928832 |
|---|---|
| author | HU Run YAO Pei LI Junen GUI Renjie DUAN Huaxin |
| author_facet | HU Run YAO Pei LI Junen GUI Renjie DUAN Huaxin |
| author_sort | HU Run |
| collection | DOAJ |
| description | Adoptive cell immunotherapy has been a hot spot in tumor research in recent years. Chimeric antigen receptor T cells (CAR-T) have achieved great success in hematological tumors and have changed the current tumor treatment landscape to a certain extent. However, the application of CAR-T therapy in clinics is limited due to its serious side effects and high treatment costs. Natural killer (NK) cells are important immune cells in the body and have native cytotoxicity and well safety. NK cells based on CAR engineering (CAR-NK) have shown powerful anti-tumor activity and safety in preclinical research and could be the next generation of CAR platform-based cellular immunotherapy. This review will systematically introduce the current research status of CAR-NK cells in lymphoma. |
| first_indexed | 2024-03-08T18:41:39Z |
| format | Article |
| id | doaj.art-36a572844e2b4c7d8be0d233e577af35 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-03-08T18:41:39Z |
| publishDate | 2023-12-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-36a572844e2b4c7d8be0d233e577af352023-12-29T06:02:13ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782023-12-0150121243124810.3971/j.issn.1000-8578.2023.23.06648578.2023.23.0664Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of LymphomaHU Run0YAO Pei1LI Junen2GUI Renjie3DUAN Huaxin4Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410005, ChinaDepartment of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410005, ChinaDepartment of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410005, ChinaDepartment of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410005, ChinaDepartment of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410005, ChinaAdoptive cell immunotherapy has been a hot spot in tumor research in recent years. Chimeric antigen receptor T cells (CAR-T) have achieved great success in hematological tumors and have changed the current tumor treatment landscape to a certain extent. However, the application of CAR-T therapy in clinics is limited due to its serious side effects and high treatment costs. Natural killer (NK) cells are important immune cells in the body and have native cytotoxicity and well safety. NK cells based on CAR engineering (CAR-NK) have shown powerful anti-tumor activity and safety in preclinical research and could be the next generation of CAR platform-based cellular immunotherapy. This review will systematically introduce the current research status of CAR-NK cells in lymphoma.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0664chimeric antigen receptornatural killer cellslymphomaimmunotherapy |
| spellingShingle | HU Run YAO Pei LI Junen GUI Renjie DUAN Huaxin Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma Zhongliu Fangzhi Yanjiu chimeric antigen receptor natural killer cells lymphoma immunotherapy |
| title | Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma |
| title_full | Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma |
| title_fullStr | Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma |
| title_full_unstemmed | Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma |
| title_short | Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma |
| title_sort | research progress of chimeric antigen receptor nk cells in treatment of lymphoma |
| topic | chimeric antigen receptor natural killer cells lymphoma immunotherapy |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0664 |
| work_keys_str_mv | AT hurun researchprogressofchimericantigenreceptornkcellsintreatmentoflymphoma AT yaopei researchprogressofchimericantigenreceptornkcellsintreatmentoflymphoma AT lijunen researchprogressofchimericantigenreceptornkcellsintreatmentoflymphoma AT guirenjie researchprogressofchimericantigenreceptornkcellsintreatmentoflymphoma AT duanhuaxin researchprogressofchimericantigenreceptornkcellsintreatmentoflymphoma |